Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Biologics for treating atopic dermatitis

5 October 2026

Condition

Skin

-

Published on 05 Oct 2026
Last Updated on 05 Oct 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Lebrikizumab 250 mg solution for injection in pre-filled pen for treating moderate-to-severe atopic dermatitis in patients who have had an inadequate response, intolerance or contraindication to at least one systemic therapy such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil.

Funding status

Lebrikizumab 250 mg solution for injection in pre-filled pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 December 2026.

Lebrikizumab should be used in line with the additional clinical criteria listed in the Annex.

MAF assistance does not apply to any formulations or strengths of dupilumab or nemolizumab for treating atopic dermatitis.

Biologics for treating atopic dermatitis (Published 5 Oct 2026) [PDF, 195.98 KB] (opens in new tab)